Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
Spyre Therapeutics will present the first congress data covering all three of its IBD antibodies — SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23) — at United European Gastroenterology Week 2026 in Barcelona. The data come from the SKYLINE Phase 2 platform trial, where the antibodies are being tested as monotherapies and pairwise combinations; new preclinical data show additive efficacy of the combined mechanisms.
Key figures
- Drug Name
- SPY001, SPY002, SPY003
- Phase Of Trial
- Phase 2
- Study name
- SKYLINE
- Antibody count
- 3
- Combo data timing
- next year
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.